SanBio Company Limited

Tokyo Stock Exchange 4592.T

SanBio Company Limited Cash and Short-Term Investments for the year ending January 31, 2024: USD 30.31 M

SanBio Company Limited Cash and Short-Term Investments is USD 30.31 M for the year ending January 31, 2024, a -41.42% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

SanBio Company Limited Cash and Short-Term Investments for the year ending January 31, 2023 was USD 51.73 M, a 30.76% change year over year.
SanBio Company Limited Cash and Short-Term Investments for the year ending January 31, 2022 was USD 39.56 M, a -66.79% change year over year.
SanBio Company Limited Cash and Short-Term Investments for the year ending January 31, 2021 was USD 119.15 M, a -5.39% change year over year.
SanBio Company Limited Cash and Short-Term Investments for the year ending January 31, 2020 was USD 125.94 M, a 10.11% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Tokyo Stock Exchange: 4592.T

SanBio Company Limited

CEO	Mr. Keita Mori MBA
IPO Date	April 8, 2015
Location	Japan
Headquarters	St. Luke Tower
Employees	29
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years